1. Home
  2. CERO

as 06-27-2025 1:30pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Stocks

Nasdaq

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Founded: 2017 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 3.5M IPO Year: N/A
Target Price: $45.00 AVG Volume (30 days): 3.3M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -241.81 EPS Growth: N/A
52 Week Low/High: $6.71 - $895.40 Next Earning Date: 08-13-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

CERO Daily Stock ML Predictions

Share on Social Networks: